• What is the RTDC?
• Learn More
• Take Action
• Information for Physicians
• Information for Investigators
• News & Events
• Participating Clinical Centers

• Contact Information

University of Wisconsin

Contact Information:

Clinical Trials:

5801: The Incidence of Thromboembolic Events in Patients with Antibodies to Heparin-PF4 after Cardiac Bypass

About Us:

A researcher at the University of Wisconsin named Karl Paul Link discovered the anticoagulant drug Warfarin, when a farmer sought help for his cattle that were bleeding to death after eating spoiled sweet clover. The spoiled clover contained an anticoagulant. Professor Link isolated and purified this substance, and later patented it under the name warfarin. The drug was found to be a potent rodenticide, and later (as Coumadin ®) became widely used as an anticoagulant in humans. Coumadin ® remains the mainstay of anticoagulant treatment for patients with hypercoagulable states.

Dr. Hansen is Assistant Professor of Medicine and joined the University of Wisconsin Faculty in 2001. Since that time, she has received grant support from the Wisconsin Lupus and Arthritis Foundations for research on antiphospholipid antibody syndrome. Her interest in antiphospholipid antibody syndrome began when she was a fellow at Duke University, and she has collaborated with Dr Ortel from Duke University since that time. Her main focus has been the search for risk factors that lead to thrombosis among subjects who have an antiphospholipid antibody.

Dr. Williams is Professor of Medicine, Pathology and Laboratory Medicine at the University of Wisconsin. He is Chief of the UW Section of Hematology, and Director of the Special Coagulation Laboratory at the University of Wisconsin Hospitals and Clinics. He has a long-standing interest in the diagnosis and treatment of hemorrhagic and thrombotic disorders, including antiphospholipid antibody syndrome and various inherited forms of thrombophilia (hypercoagulable states). He has been named to the "Best Doctors in America " list as well as Madison Magazine's "Best Doctors in Madison " list.

Useful Links:

Arthritis Foundation

Lupus Foundation

American College of Rheumatology

Publications:

1. Hansen KE, Kong D, Moore KD, Ortel TL: Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001 Sept;28(9):2018-24.

2. Hansen KE, Moore KD, Ortel TL, Allen NB: Antiphospholipid antibodies in patients with polyarteritis nodosa and Wegener's Granulomatosis. Arthritis Rheum 1999;42:2250-2252.

3. Hansen KE: Antiphospholipid antibodies. In West S Ed. Rheumatology Secrets, Philadelphia: Mosby, 2002, pp 184-192.

4. Hansen KE , Kramm HL, Boh D, Bell CB, Perry S, Potti A, Ortel TL: Risk factors for thrombosis and the beneficial effect of aspirin in patients with antiphospholipid antibodies [abstract]. Blood 2004;104(11):279a.

5. McCroskey RD, Phillips A, Mott F, Williams EC. Antiphospholipid antibodies and adrenal hemorrhage. Am J Hematol 1991; 36:60-62.

6. Williams EC. Plasma alpha-2 antiplasmin activity: Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med 1989; 149:1769-1772.

7. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Int Med 1992;152:317-320.

8. Williams EC, Huppert BJ, Asakura S. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison to other plasma and platelet proteins. J Lab Clin Med 1992;120:159-67.